Global Ventilator Associated Pneumonia (VAP) Pipeline Review, H2 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Ventilator Associated Pneumonia (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

This report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 5, 8, 1, 10, 6 and 1 respectively.

The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia.
• The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Ventilator Associated Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (Infectious Disease)

Key Topics Covered:

• Introduction
• Ventilator Associated Pneumonia (VAP) - Overview
• Ventilator Associated Pneumonia (VAP) - Therapeutics Development
• Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment
• Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development
• Ventilator Associated Pneumonia (VAP) - Drug Profiles
• Ventilator Associated Pneumonia (VAP) - Dormant Projects
• Ventilator Associated Pneumonia (VAP) - Discontinued Products
• Ventilator Associated Pneumonia (VAP) - Product Development Milestones
• Appendix

Companies Mentioned

• Antabio SAS
• Aridis Pharmaceuticals Inc
• AstraZeneca Plc
• Bioversys AG
• Cumberland Pharmaceuticals Inc
• CytaCoat AB
• Destiny Pharma Plc
• Dong-A Socio Holdings Co Ltd
• EnBiotix Inc
• Helperby Therapeutics Group Ltd
• Hypo-Stream Ltd
• La Jolla Pharmaceutical Company
• Meiji Seika Pharma Co Ltd
• Merck & Co Inc
• Motif Bio Plc
• Nabriva Therapeutics Plc
• Nosopharm SAS
• Peptineo
• Pulmobiotics SL
• Qilu Pharmaceutical Co Ltd
• Shionogi & Co Ltd
• Spero Therapeutics Inc
• TGV-Inhalonix Inc
• VenatoRx Pharmaceuticals Inc
• Wockhardt Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jwx2id

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.